QUENCH MEDICAL, INC.
Medtech · Private
Dry powder inhaled chemotherapy formulation for direct lung delivery of cancer drugs
- Grants
- $5.4M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Treating severe asthma in the small airways: a novel inhaled dry powder formulation | $224,844 | |
| Federal grant | Department of Health and Human Services · Phase II · Treating severe asthma in the small airways with a highly efficient and penetrating inhaled dry powder | $1,247,479 | |
| Federal grant | Department of Health and Human Services · Phase I · Treating non-small cell lung tumors with a novel inhaled dry powder chemotherapeutic formulation | $400,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Treating severe asthma in the small airways with a highly efficient and penetrating inhaled dry powder | $802,302 | |
| Federal grant | Department of Health and Human Services · Phase I · Stop pulmonary airleaks with a novel inhaled dry powder aerosol | $299,838 | |
| Federal grant | Department of Health and Human Services · Phase II · Treating non-small cell lung tumors with a novel inhaled dry powder chemotherapeutic formulation | $1,127,538 | |
| Federal grant | Department of Health and Human Services · Phase II · Treating non-small cell lung tumors with a novel inhaled dry powder chemotherapeutic formulation | $874,452 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel inhaled dry powder psychoplastogenic formulation for treating persons with opioid use disorder | $404,917 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1644 | SPHEROFILL, LLC | — | — |
| 1645 | Microdermics Inc. | — | $493K |
| 1646 | Carolina Molecular Inc. | — | $1.1M |
| 1647 | QUENCH MEDICAL, INC. | — | — |
| 1648 | Akeyna Inc. | — | $300K |
| 1649 | AGIGA, INC. | — | $3.6M |
| 1650 | PREDICOR LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Dry Powder Inhalation Delivery Of Pharmaceuticalsapplication
- Dry Powder Inhalation Delivery Of Pharmaceuticalsapplication
- Dry Powder Inhalation Delivery Of Pharmaceuticalsapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.